Value of gadolinium in brain MRI examinations for developmental delay
(2006) In Pediatric Neurology 35(2). p.126-130- Abstract
- The aim of this study was to evaluate the added utility of gadolinium administration in the magnetic resonance imaging evaluation of developmental delay in children less than 2 years of age. A computerized retrospective study identified all brain magnetic resonance imaging examinations using gadolinium performed at our institution from 1995-2002 for children under the age of 2 years. Review of the clinical records and magnetic resonance imaging reports identified 170 brain magnetic resonance imaging examinations that were performed for developmental delay. Magnetic resonance imaging studies with enhancing lesions were reviewed by two staff neuroradiologists and two radiology residents. Contrast administration was rated as essential,... (More)
- The aim of this study was to evaluate the added utility of gadolinium administration in the magnetic resonance imaging evaluation of developmental delay in children less than 2 years of age. A computerized retrospective study identified all brain magnetic resonance imaging examinations using gadolinium performed at our institution from 1995-2002 for children under the age of 2 years. Review of the clinical records and magnetic resonance imaging reports identified 170 brain magnetic resonance imaging examinations that were performed for developmental delay. Magnetic resonance imaging studies with enhancing lesions were reviewed by two staff neuroradiologists and two radiology residents. Contrast administration was rated as essential, helpful, or not helpful for each study. In the 107 patients in whom developmental delay was the primary concern, there were no cases in which the findings would have been missed without gadolinium administration. In the 63 patients in whom developmental delay was a secondary concern, there were several cases (11%) where contrast was helpful but not essential in reaching a radiologic diagnosis. In conclusion, intravenous gadolinium has an extremely low yield in children under the age of 2 where developmental delay is the primary concern. In young children for whom developmental delay is a secondary concern, we advocate the use of gadolinium particularly where tumor or infection is clinically suspected. (c) 2006 by Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/398248
- author
- Foerster, Bradley R. ; Ksar, Jamal ; Petrou, Myria ; Eldevik, Petr O. ; Maly, Pavel LU ; Carlson, Martha D. and Sundgren, Pia C.
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pediatric Neurology
- volume
- 35
- issue
- 2
- pages
- 126 - 130
- publisher
- Elsevier
- external identifiers
-
- wos:000239697900009
- pmid:16876010
- scopus:33746198198
- ISSN
- 0887-8994
- DOI
- 10.1016/j.pediatrneurol.2006.02.014
- language
- English
- LU publication?
- yes
- id
- 76a74109-ac85-4a9d-a776-219ab86b9545 (old id 398248)
- date added to LUP
- 2016-04-01 12:23:32
- date last changed
- 2022-01-27 03:05:25
@article{76a74109-ac85-4a9d-a776-219ab86b9545,
abstract = {{The aim of this study was to evaluate the added utility of gadolinium administration in the magnetic resonance imaging evaluation of developmental delay in children less than 2 years of age. A computerized retrospective study identified all brain magnetic resonance imaging examinations using gadolinium performed at our institution from 1995-2002 for children under the age of 2 years. Review of the clinical records and magnetic resonance imaging reports identified 170 brain magnetic resonance imaging examinations that were performed for developmental delay. Magnetic resonance imaging studies with enhancing lesions were reviewed by two staff neuroradiologists and two radiology residents. Contrast administration was rated as essential, helpful, or not helpful for each study. In the 107 patients in whom developmental delay was the primary concern, there were no cases in which the findings would have been missed without gadolinium administration. In the 63 patients in whom developmental delay was a secondary concern, there were several cases (11%) where contrast was helpful but not essential in reaching a radiologic diagnosis. In conclusion, intravenous gadolinium has an extremely low yield in children under the age of 2 where developmental delay is the primary concern. In young children for whom developmental delay is a secondary concern, we advocate the use of gadolinium particularly where tumor or infection is clinically suspected. (c) 2006 by Elsevier Inc. All rights reserved.}},
author = {{Foerster, Bradley R. and Ksar, Jamal and Petrou, Myria and Eldevik, Petr O. and Maly, Pavel and Carlson, Martha D. and Sundgren, Pia C.}},
issn = {{0887-8994}},
language = {{eng}},
number = {{2}},
pages = {{126--130}},
publisher = {{Elsevier}},
series = {{Pediatric Neurology}},
title = {{Value of gadolinium in brain MRI examinations for developmental delay}},
url = {{http://dx.doi.org/10.1016/j.pediatrneurol.2006.02.014}},
doi = {{10.1016/j.pediatrneurol.2006.02.014}},
volume = {{35}},
year = {{2006}},
}